Brexit Impact Statement
As the manufacturer and supplier of an essential wound care treatment BioMonde have been continually monitoring the United Kingdom’s exit from the European Union until the transition period ends on the 1st of January 2021. We can provide reassurance that our supply chain will not be impacted. We do not believe that the supply of Larval Therapy will be interrupted within the UK mainland.
Republic of Ireland
We have been advised that the Department of Health (Ireland) are treating larvae as a special exception to the Exempt Medicinal Product classification and delivery of larvae will not be accepted in the ROI from the UK from the 1st of January 2021. BioMonde, as the largest supplier of medicinal larvae in Europe will continue to supply Republic of Ireland customers from our manufacturing site in Germany. Orders should be placed by calling our German site on +49 180 2 466663 or contacting us by email at firstname.lastname@example.org.
Brexit is continuing to cause delays at the sea border due to increased security checks despite packages being sent from within the UK. This, in addition to the ongoing impact of COVID-19 on shipping volume, social distancing and self-isolation rules has led to some of our next-day delivery services failing with some packages taking two days to arrive. We have seen this issue improve over time so please talk to our customer service team on 0345 230 1810 to discuss your shipping options.
If you have any queries about the impact in receiving larvae due to Brexit please contact us at 0345 230 1810 or via email@example.com